PDS Biotechnology Corporation (NASDAQ:PDSB) Short Interest Down 16.3% in April

Key Points

• Short interest fell 16.3% in April to 1,717,509 shares (about 3.4% of the stock) with a short‑interest ratio of roughly 1.2 days based on average daily volume.
• Multiple institutions increased or initiated stakes—Armistice Capital opened a ~$2.18M position and firms like Squarepoint, Commonwealth and Susquehanna substantially boosted holdings—bringing institutional ownership to about 26.84%.
• Analyst sentiment is mixed: the consensus is a "Hold" with an average target of $9, while HC Wainwright is a Buy at $15 and Weiss Ratings maintains a Sell.

PDS Biotechnology Corporation (NASDAQ:PDSB - Get Free Report) saw a significant decrease in short interest in the month of April. As of April 15th, there was short interest totaling 1,717,509 shares, a decrease of 16.3% from the March 31st total of 2,050,834 shares. Currently, 3.4% of the company's stock are sold short. Based on an average daily trading volume, of 1,466,066 shares, the short-interest ratio is presently 1.2 days.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC bought a new position in PDS Biotechnology in the 4th quarter valued at about $2,182,000. Squarepoint Ops LLC boosted its holdings in shares of PDS Biotechnology by 116.1% during the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company's stock worth $295,000 after acquiring an additional 156,662 shares during the period. Commonwealth Equity Services LLC grew its position in shares of PDS Biotechnology by 117.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company's stock valued at $151,000 after purchasing an additional 106,300 shares during the last quarter. Susquehanna International Group LLP increased its stake in shares of PDS Biotechnology by 603.7% during the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company's stock worth $95,000 after purchasing an additional 80,937 shares during the period. Finally, Jane Street Group LLC acquired a new stake in PDS Biotechnology during the 2nd quarter worth approximately $92,000. Institutional investors and hedge funds own 26.84% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PDSB. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of PDS Biotechnology in a research report on Tuesday, April 21st. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 target price on shares of PDS Biotechnology in a report on Wednesday, April 15th. Finally, Wall Street Zen upgraded PDS Biotechnology from a "sell" rating to a "hold" rating in a report on Saturday, April 4th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, PDS Biotechnology has an average rating of "Hold" and an average target price of $9.00.

PDS Biotechnology Stock Up 3.3%

PDSB opened at $1.01 on Friday. The stock's fifty day simple moving average is $0.81 and its 200 day simple moving average is $0.85. PDS Biotechnology has a 1-year low of $0.51 and a 1-year high of $1.92. The stock has a market cap of $54.67 million, a PE ratio of -1.34 and a beta of 1.20. The company has a current ratio of 2.98, a quick ratio of 2.98 and a debt-to-equity ratio of 1.27.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.06. As a group, research analysts expect that PDS Biotechnology will post -0.59 earnings per share for the current year.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company's proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.